Sabby Management’s InMed Pharmaceuticals INM Stock Holding History

Sabby Management’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$142K	Buy	220,260 +18,627	+9%	+$17.6K	0.32%	19
2025 Q4	$214K	Sell	201,633 -18,365	-8%	-$30.5K	0.31%	23
2025 Q3	$482K	Buy	+219,998	New	+$530K	0.56%	16
2024 Q3	–	Sell	-15,362	Closed	-$81.6K	–	53
2024 Q2	$81.6K	Sell	15,362 -2,724	-15%	-$15.6K	0.05%	29
2024 Q1	$132K	Sell	18,086 -7,511	-29%	-$55.2K	0.08%	28
2023 Q4	$213K	Buy	+25,597	New	+$248K	0.21%	22
2022 Q4	–	Sell	-764	Closed	-$101K	–	118
2022 Q3	$101K	Buy	+764	New	+$141K	0.13%	80

Other funds holding INM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $431M AUM 20.62% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Sabby Management's INM Position: Q1 2026 in Review

Sabby Management increased its InMed Pharmaceuticals (INM) stake by 9.2% in Q1 2026, buying an estimated $17.6K and bringing the position to 220,260 shares worth $142K. The position accounts for 0.32% of the portfolio, ranked #19.

Sabby Management first reported a position in INM in Q3 2022 and has held it in 7 quarters since. The position peaked at $482K in Q3 2025. 9 funds tracked by Wall St. Rank hold INM as of Q1 2026.

Sabby Management held 220,260 shares of InMed Pharmaceuticals worth $142K as of Q1 2026.
Sabby Management bought 18,627 InMed Pharmaceuticals shares in Q1 2026, an estimated $17.6K.
InMed Pharmaceuticals made up 0.32% of Sabby Management's portfolio in Q1 2026, its #19 holding.
Sabby Management first reported a position in InMed Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
Sabby Management's InMed Pharmaceuticals position peaked at $482K in Q3 2025.
9 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.